Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia

European Respiratory Journal

Volumn 32, Issue 3, 2008, Pages 726-732

  Bruns, A H W ^a   Oosterheert, J J ^a   Hak, E ^a   Hoepelman, A I M ^a,b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antibiotic treatment; C reactive protein; Community acquired pneumonia; Follow up

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN G; RIFAMPICIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TISSUE LEVEL; TREATMENT OUTCOME; APACHE; BACTERIAL PNEUMONIA; BLOOD; COHORT ANALYSIS; COMMUNICABLE DISEASE; HOSPITALIZATION; MIDDLE AGED;

AGED; ANTI-BACTERIAL AGENTS; APACHE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL;

EID: 56549127312     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00003608     Document Type: Article

References (27)

1. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005; 294: 2712-2719.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72.
3. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180.
4. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest 2004; 125: 2140-2145.
5. Malhotra-Kumar S, Lammens C, Coenen S, Van HK, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007; 369: 482-490.
6. Couto RC, Barbosa JA, Pedrosa TM, Biscione FM. C-reactive protein-guided approach may shorten length of antimicrobial treatment of culture-proven late-onset sepsis: an intervention study. Braz J Infect Dis 2007; 11: 240-245.
7. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med 1999; 17: 1019-1025.
8. Coelho L, Povoa P, Almeida E, et al. Usefulness of C-reactive protein in monitoring severe community-acquired pneumonia clinical course. Crit Care 2007; 11: R92.
9. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995; 108: 1288-1291.
10. Menendez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalized community-acquired Pneumonia. Thorax 2008; 63: 447-452.
11. Prat C, Dominguez J, Andreo F, et al. Procalcitonin and neopterin correlation with etiology and severity of pneumonia. J Infect 2006; 52: 169-177.
12. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006; 333: 1193-1197.
13. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
14. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
16. Jacobs E. Serological diagnosis of Mycoplasma pneumoniae infections: a critical review of current procedures. Clin Infect Dis 1993; 17: Suppl. 1, S79-S82.
17. Stout JE, Yu VL. Legionellosis. N Engl J Med 1997; 337: 682-687.
18. Schouten JA. Revised SWAB guidelines for antimicrobial therapy of community acquired pneumonia. Amsterdam, SWAB, 2005. Available from www.swab.nl.
19. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 1452-1457.
20. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15: Suppl. 1, S62-S88.
21. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121: 219-225.
22. van der Meer V, Neven AK, van den Broek PJ, Assendelft WJ. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ 2005; 331: 26-32.
23. Man SF, Sin DD. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 78-82.
24. Perren A, Cerutti B, Lepori M, et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection 2008; 36: 163-166.
25. Holmberg H, Bodin L, Jonsson I, Krook A. Rapid etiological diagnosis of pneumonia based on routine laboratory features. Scand J Infect Dis 1990; 22: 537-545.
26. Garcia VE, Martinez JA, Mensa J, Sanchez F, Marcos MA, de Roux A, Torres A. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 2003; 21: 702-705.
27. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.